Cerestat CNS 1102 data

CNSI (Cambridge, Mass.) reported on an open-label Phase 1/II trial in 29 patients who had suffered

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE